

### **Quality Management, 7° Edition Standard**

# Immune effector cells standards

Riccardo Saccardí

Florence

Gruppo Italiano Interdisciplinare

GITMO

Manipolazione e Aferesi per Terapie Cellulari

SIdEM

#### VI Congresso Nazionale

V ASSEMBLEA ASSOCIATIVA GIIMA

29 NOVEMBRE 2019 ROMA

# CONFLICT OF INTEREST DISCLOSURES

No disclosures



- Adoptive T cell transfer (ACT) is a new area of transfusion medicine involving the infusion of lymphocytes to mediate antitumor, antiviral, or antiinflammatory effects.
- Durable clinical responses of otherwise treatment-refractory cancers have recently been achieved, revealing the power and potential of ACT.
- The field has rapidly advanced from a promising form of immuno-oncology in preclinical models to the recent commercial approvals of chimeric antigen receptor (CAR) T cells to treat leukemia and lymphoma.
- A gradual shift from academic research to a pharma-driven clinical practice





4

# Immune Effector Cells and JACIE Standard

- Starting with version 6.1, the Standards include new items specifically developed for other cellular therapy products, with special reference to immune effector cells (IEC).
- This reflects the rapidly evolving field of cellular therapy through mainly, but not exclusively, genetically modified cells, such as CAR-T cells.
- The Standards do not cover the manufacturing of such cells, but include the chain of responsibilities where the product is provided by a third party and ensure the competence of the personnel in the management of adverse events related to the infusion.





### **FACT-JACIE Standards (7th Ed) apply to:**

- 1. Hematopoietic progenitor cells from hematopoietic sources
- 2. Nucleated cells or mononuclear cells from any hematopoietic tissue source collected for therapeutic use other than as hematopoietic progenitor cells
- 3. Immune effector cells derived from these sources, defined broadly as any cells, in vitro modified or not, that are capable of eliciting or modulating an immune response.
- This broad designation includes cellular therapy products with widely diverse manufacturing methods, constructs, clinical indications, and safety and toxicity profiles.





## **FACT-JACIE Standards: IECs and QM**

B7.11 There shall be policies or Standard Operating Procedures addressing the administration of immune effector cells and management of complications, if applicable.

B7.11.1 There shall be a **consultation with the referring physician** prior to initiation of immune effector cellular therapy to review the goal and plan of the treatment.

B7.11.2 There shall be regular **assessment of the recipient to detect complications,** including cytokine release syndrome and neurologic dysfunction.

B7.11.3 There shall be a **written plan for rapid escalation of care**, increased intensity of monitoring, and relevant workup to address complications.

B7.11.4 **Communication** to the clinical staff, intensive care unit, emergency department, and pharmacy shall be timely.


B7.11.5 The Clinical Program shall have written guidelines for management of complications, including the use of cytokine blocking agents and corticosteroid administration.



Haematologica HAEMATOL/2019/229781 Version 3

Management of Adults and Children undergoing CAR T-cell therapy: Best Practice Recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)

Ibrahim Yakoub-Agha<sup>1</sup>, Christian Chabannon<sup>2</sup>, Peter Bader<sup>3</sup>, Grzegorz W. Basak<sup>4</sup>, Halvard Bonig<sup>5</sup>, Fabio Ciceri<sup>6</sup>, Selim Corbacioglu<sup>7</sup>, Rafael F. Duarte<sup>8</sup>, Hermann Einsele<sup>9</sup>, Michael Hudecek<sup>9</sup>, Marie José Kersten<sup>10</sup>, Ulrike Köhl<sup>11</sup>, Jürgen Kuball<sup>12</sup>, Stephan Mielke<sup>13</sup>, Mohamad Mohty<sup>14</sup>, John Murray<sup>15</sup>, Arnon Nagler<sup>16</sup>, Stephen Robinson<sup>17</sup>, Riccardo Saccardi<sup>18</sup>, Fermin Sanchez-Guijo<sup>19</sup>, John A Snowden<sup>20</sup>, Micha Srour<sup>21</sup>, Jan Styczynski<sup>22</sup>, Alvaro Urbano-Ispizua<sup>23</sup>, Patrick J. Hayden<sup>24</sup> and Nicolaus Kröger<sup>25</sup>



Haematologica, online ed, 2019



Yakoub-Agha et Al, Haematologica, online ed, 2019

Period	SPCs and protocols	EBMT recommendations	Comments		Type of therapy	SPCs	EBMT recommendations	Comments
	Some protocols require 5-14 days hospitalisation after the infusion	Ideally, 14 days hospitalisation	Shorter hospitalisation periods as well as outpatient follow-up are possible in centres that can provide 24/7 contact with immediate availability of specialist inpatient care. Patients have to be located within 30 minutes of the centre CRS and, in particular, ICANS can occur after the patients has left the hospital. In addition, life-threatening complications may occur during this period e.g. septic shock in neutropenic patients		Allo-HCT	No guidance	Patients should be off immunosuppression and GVHD-free	A minimum of one month is recommended
Day 0 to Day +14 post- infusion					DLI	No guidance	Four weeks	6-to-8 weeks may be safer to rule out any GVHD
					High-dose chemotherapy	No guidance	3-to-4 weeks depending on the intensity of the chemotherapy	Recovery from cytopenias is required
	Some protocols require that patients be located within 30 to 60 minutes of the centre	Patients have to be located within 60 minutes of the treating unit or a well- equipped centre* The continuous presence of a caregiver who is educated to recognize the signs and symptoms of CRS and ICANS is required			CNS-directed therapy	No guidance	One week	
					Short-acting cytotoxic/anti- proliferative drugs	No guidance	Three days	Recovery from cytopenias is required
From hospital discharge to Day +28 post-infusion					Systemic corticosteroids	No guidance	ldeall y, seven days to minimise any effect on lymphocyte collection	A shorter period of as few as three days was considered acceptable by Kansagra et al (12) Re gardless of timing, an ALC>0.2 x10 <sup>7</sup> /L is preferable given the likely effect of recent corticosteroids on lymphocyte quality

Table 7. Recommendations regarding the first month after CAR-T infusion

Table 4. Wash-out period before leukapheresis (adapted from Kansagra et al, BBMT 2018)

# JACIE ACCREDITATION: APPLICANT TOOLS

### The Standard

B7.11.2 There shall be regular assessment of the recipient to detect complications, including cytokine release syndrome and neurologic dysfunction.

## The Manual

#### Example(s):

 In addition to IND requirements, investigator experience may generate ideas for detecting complications.
 Attending physicians may want to request additional laboratory testing, such as Creactive protein, lactate dehydrogenase, ferritin, and fibrinogen. For example, evaluating fibrinogen periodically after CAR administration may be useful for early detection of disseminated intravascular coagulation (DIC).





# **Intensive Care Unit**



- Close interaction with ICU team
- Education for the ICU team in CAR-T adverse events
- Communication
- Patient monitoring
- Transfer of patients
- <u>NOTE</u>: substantial variation in how IC is organised; typically difficult to <u>guarantee</u> exclusive access for CAR-T patients




#### Standards: Outcome review



- B4.7.3 Review of outcome analysis and/or product efficacy shall include at a minimum:
  - B4.7.3.2 For immune effector cells, an endpoint of clinical function as approved by the Clinical Program Director.
- B4.7.3.3 Overall and treatmentrelated morbidity and mortality at
  - thirty (30) days
  - one hundred (100) days,
  - one (1) year

after transplantation cellular therapy product administration.



#### Standards: Long term follow-up

- B7.12.1 Policies or Standard Operating Procedures for monitoring by appropriate specialists of recipients for post-cellular therapy late effects, including at a minimum:
  - Endocrine and reproductive function and osteoporosis.
  - Cardiovascular risk factors.
  - Respiratory function.
  - Chronic renal impairment.
  - Secondary malignancies.
  - Growth and development of pediatric Follow up! patients.

@JACIE EBMT



12







- Minimum experience established
- Continuous education = 10 hours per year
  - in transplant-related areas
- Some specific areas of competency (mostly in Part B)
- No specific staffing numbers
  - "Adequate", "satisfactory"
- Provision for trained back-up staff





# **IECs: personnel training**

B3.7.3 **Nurses** shall have received specific training and maintain competence in the transplant-related skills that they routinely practice including:

 B3.7.3.4 Detection and management of immune effector cellular therapy complications including, but not limited to, those listed in B3.7.3.4.

Because cytokine release syndrome requires rapid care and attention, nurse training on this condition should include institutional policies on accessing and administering pertinent medications (such as tocilizumab).

B3.8.2 Training and knowledge of designated **pharmacists** shall include:

B3.8.2.2 Adverse events including, but not limited to, cytokine release syndrome and neurological toxicities.





Oncology Nurses Must Watch for CAR T-Cell Therapy Side Effects

By Bryant Furlow
Tuesday, May 9, 2017
Conferences 
ONS 2017
Hematologic Malignancies
Oncology Nursing



# **JACIE ACCREDITATION:**

	-	-	_	-		_
6.01ref HSCT	6,01 standard HSCT	Guidance	Applicant's assessment	Source of evidence and explanatory text	Inspector's Assessment	Inspector's Comments (support your answers with additional
_	_			_		information)
B1.2.1	If cellular therapy products are received directly by the Clinical Program from a third-party provider, the following responsibilities at a minimum shall be defined in a written agreement:	Explanation:		Please indicate here evidence that responds to this standard	₩ ₩	
B1.2.1.1	Traceability and chain of custody of cellular therapy products.			Please indicate here evidence that responds to this standard		

### **IECs Standards: Chain of Responsabilities**

B1.2.1 If the **Clinical Program or an intermediary facility receives cellular therapy products directly from a third-party provider**, the following responsibilities shall be defined, at a minimum, by a written agreement:

- B1.2.1.1 Traceability and chain of custody of cellular therapy products.
- B1.2.1.2 Cellular therapy product **storage and distribution**.
- B1.2.1.3 Verification of cellular therapy product **identity.**
- B1.2.1.4 Review and verification of product specifications provided by the manufacturer, if applicable
- B1.2.1.5 Readily available access to a summary of documents used to determine allogeneic **donor eligibility**.
- B1.2.1.6 Documented evidence of allogeneic **donor eligibility screening** and testing in accordance with applicable laws and regulations.









- Standards are a 'work in progress'
  - Technology moving fast
- Inspector pool and lack of experience of IECs
- IEC definition is very broad in order to encompass all possible IECs
  - Maybe 'overkill' for low-risk CT products

#### **Current thinking**

- Take risk-based approach
- Thresholds for defining the classes of risk to be defined

Low Risk	High Risk
Tumour infiltrating lymphocytes (TILs)	CAR-T cells
Dendritic cells	NK cells
Viral specific cytotoxic T	TILs with adjuvant
cells (vCTLs)	therapy – IL2
Mesenchymal stromal cells (MSCs)	
Cytokine Induced Killer (CIK) cells	

@JACIE\_EBMT

### CAR-T PROGRAM: RESPONSABILITA' E RUOLI

	Azione	Responsabilità		
	Selezione e screening del paziente	Centro clinico		
	La raccolta mediante linfocitoaferesi (Cropreservazione -> Novartis)			
	La spedizione alla cell factory			
	Il trattamento delle cellule ed il loro congelamento	Produttore		
¢,	L'invio del prodotto finito al Centro clinico		•	
	Il controllo e lo stoccaggio controllato in vapori di azoto			
La somministrazione di una chemioterapia immunoablativa				
	Lo scongelamento e la somministrazione delle cellule	Centro clinico		
	Monitoraggio clinico e trattamento delle complicanze a breve termine			
•	Il monitoraggio a lungo termine (15 anni)		•	





# **Involved Services**

In all the involved areas, <u>evidence</u> of adequate personnel training, manpower, validated procedures, product identification and traceability, <u>efficient</u> <u>communication</u>, shall be in place


Service	Action		
Outpatient	Patient selection		
Inpatient/Outpatient Unit	Clinical monitoring and Therapy		
Apheresis unit	Collection, Product quality		
Pharmacy	Drug availability		
ICU	Plan for rapid care escalation		
Neurology	Clinical monitoring and Therapy		
Processing lab	Storage and thawing		
Data Managing	FU and Registry Report		



# Implementation of a IEC program

•An implementation plan aimed to fulfill all the accreditation requirements, engaging all the professionals, services and involved infrastructures is essential

•Before starting, an exhaustive estimation of eligible patients, general needs and costs has to be carried out and approved by the Competent Authority



Courtesy of Dr. Minninna, Utrecht



# **Thanks!**

Any questions? riccardo.saccardi@unifi.it